AMOXICILLIN/CLAVULANAT EFFICIENCY FOR TREATMENT OF CHILDREN WITH COMMUNITY-ACQUIRED PNEUMONIA

Research goal — comparative evaluation of efficiency of amoxicillin/clavulanat versus unprotected penicillins and first generation cephalosporins for treatment of children with acute community acquired pneumonia. 62 children with acute pneumonia took part in the research. The main group was comprise...

Full description

Saved in:
Bibliographic Details
Main Authors: O.I. Pikuza, A.M. Zakirova, E.A. Samorodnova, Kh.M. Vakhitov, T.B. Moroz
Format: Article
Language:Russian
Published: Union of pediatricians of Russia 2006-12-01
Series:Педиатрическая фармакология
Online Access:https://www.pedpharma.ru/jour/article/view/597
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1839587245221216256
author O.I. Pikuza
A.M. Zakirova
E.A. Samorodnova
Kh.M. Vakhitov
T.B. Moroz
author_facet O.I. Pikuza
A.M. Zakirova
E.A. Samorodnova
Kh.M. Vakhitov
T.B. Moroz
author_sort O.I. Pikuza
collection DOAJ
description Research goal — comparative evaluation of efficiency of amoxicillin/clavulanat versus unprotected penicillins and first generation cephalosporins for treatment of children with acute community acquired pneumonia. 62 children with acute pneumonia took part in the research. The main group was comprised of 47 children aged 3–17 who received amoxicillin/clavulanat, comparison group — of 16 children who received unprotected penicillins or first generation cephalosporin. Treatment efficiency was evaluated by the main clinical symptoms changes dynamics. Amoxicillin/clavulanat clinical efficiency amounted to 87,23%. Compared to comparison group, treatment with amoxicillin /clavulanat helped to speed up reduction of inflammatory processes in lungs, prevent the need for refresher courses of treatment with antimicrobials, reduce the time of stay in hospital and total amount of received medication. Research results prove the advisability of more extensive amoxicillin/clavulanat use for treatment of patients with acute community acquired pneumonia both in hospital environment and in outpatient situations.Key words: antimicrobials, amoxicillin/clavulanat, treatment, pneumonia, children.
format Article
id doaj-art-f6efb95036f843d5bff8ca890cd50f1d
institution Matheson Library
issn 1727-5776
2500-3089
language Russian
publishDate 2006-12-01
publisher Union of pediatricians of Russia
record_format Article
series Педиатрическая фармакология
spelling doaj-art-f6efb95036f843d5bff8ca890cd50f1d2025-08-03T19:21:19ZrusUnion of pediatricians of RussiaПедиатрическая фармакология1727-57762500-30892006-12-01356062593AMOXICILLIN/CLAVULANAT EFFICIENCY FOR TREATMENT OF CHILDREN WITH COMMUNITY-ACQUIRED PNEUMONIAO.I. Pikuza0A.M. Zakirova1E.A. Samorodnova2Kh.M. Vakhitov3T.B. Moroz4Kazan State Medical UniversityKazan State Medical UniversityKazan State Medical UniversityKazan State Medical UniversityChildren department of State clinical hospital № 18, KazanResearch goal — comparative evaluation of efficiency of amoxicillin/clavulanat versus unprotected penicillins and first generation cephalosporins for treatment of children with acute community acquired pneumonia. 62 children with acute pneumonia took part in the research. The main group was comprised of 47 children aged 3–17 who received amoxicillin/clavulanat, comparison group — of 16 children who received unprotected penicillins or first generation cephalosporin. Treatment efficiency was evaluated by the main clinical symptoms changes dynamics. Amoxicillin/clavulanat clinical efficiency amounted to 87,23%. Compared to comparison group, treatment with amoxicillin /clavulanat helped to speed up reduction of inflammatory processes in lungs, prevent the need for refresher courses of treatment with antimicrobials, reduce the time of stay in hospital and total amount of received medication. Research results prove the advisability of more extensive amoxicillin/clavulanat use for treatment of patients with acute community acquired pneumonia both in hospital environment and in outpatient situations.Key words: antimicrobials, amoxicillin/clavulanat, treatment, pneumonia, children.https://www.pedpharma.ru/jour/article/view/597
spellingShingle O.I. Pikuza
A.M. Zakirova
E.A. Samorodnova
Kh.M. Vakhitov
T.B. Moroz
AMOXICILLIN/CLAVULANAT EFFICIENCY FOR TREATMENT OF CHILDREN WITH COMMUNITY-ACQUIRED PNEUMONIA
Педиатрическая фармакология
title AMOXICILLIN/CLAVULANAT EFFICIENCY FOR TREATMENT OF CHILDREN WITH COMMUNITY-ACQUIRED PNEUMONIA
title_full AMOXICILLIN/CLAVULANAT EFFICIENCY FOR TREATMENT OF CHILDREN WITH COMMUNITY-ACQUIRED PNEUMONIA
title_fullStr AMOXICILLIN/CLAVULANAT EFFICIENCY FOR TREATMENT OF CHILDREN WITH COMMUNITY-ACQUIRED PNEUMONIA
title_full_unstemmed AMOXICILLIN/CLAVULANAT EFFICIENCY FOR TREATMENT OF CHILDREN WITH COMMUNITY-ACQUIRED PNEUMONIA
title_short AMOXICILLIN/CLAVULANAT EFFICIENCY FOR TREATMENT OF CHILDREN WITH COMMUNITY-ACQUIRED PNEUMONIA
title_sort amoxicillin clavulanat efficiency for treatment of children with community acquired pneumonia
url https://www.pedpharma.ru/jour/article/view/597
work_keys_str_mv AT oipikuza amoxicillinclavulanatefficiencyfortreatmentofchildrenwithcommunityacquiredpneumonia
AT amzakirova amoxicillinclavulanatefficiencyfortreatmentofchildrenwithcommunityacquiredpneumonia
AT easamorodnova amoxicillinclavulanatefficiencyfortreatmentofchildrenwithcommunityacquiredpneumonia
AT khmvakhitov amoxicillinclavulanatefficiencyfortreatmentofchildrenwithcommunityacquiredpneumonia
AT tbmoroz amoxicillinclavulanatefficiencyfortreatmentofchildrenwithcommunityacquiredpneumonia